Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.66B 2.82B | Sales 2025 * | 23.51B 3.37B | Capitalization | 128B 18.35B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 733M | Net income 2025 * | 6.76B 969M | EV / Sales 2024 * | 5.11 x |
Net cash position 2024 * | 27.45B 3.94B | Net cash position 2025 * | 34.52B 4.95B | EV / Sales 2025 * | 3.97 x |
P/E ratio 2024 * |
25.3
x | P/E ratio 2025 * |
19.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B | |
-24.93% | 8.63B |